FDA approved for defined indicationsGLP-1 receptor agonistWorth comparing

Semaglutide

Also known as GLP-1

A well-characterized GLP-1 therapy with product-specific FDA indications and substantial human evidence.

Action boundaryconsultPrepare for a clinician

Education and decision support. This release does not generate doses, injection instructions, cycles, diagnoses, prescriptions, or vendor pathways.

What it is

Activates the GLP-1 receptor, affecting appetite, gastric emptying, and glucose-dependent insulin signaling.

FDA approved for defined indicationsMetabolic

Semaglutide

A well-characterized GLP-1 therapy with product-specific FDA indications and substantial human evidence.

Worth comparing
ReceptorknownRoutessubcutaneous, oralConfidencehigh

Visible for broad education until a goal is selected.

FDA approved for defined indications.

Useful for
  • Comparing evidence-backed medical weight-management options
  • Preparing for a prescribing consultation
Not established for
  • Casual cosmetic use without medical screening
  • Combining with another GLP-1 product without prescriber direction
Evidence receipts
FDA approved claimReviewed 2026-07-12
Chronic weight management

FDA-approved semaglutide products include an indication for long-term weight reduction in defined populations when combined with reduced-calorie diet and physical activity.

Approval is product- and indication-specific; candidacy and contraindications require a prescriber.

U.S. Food and Drug Administration: WEGOVY (semaglutide) prescribing information
Review evidence